ArticleArchives of endocrinology and metabolism2026
Challenging the recessive paradigm of Mahvash disease: heterozygous phenotypes from a novel splice-site variant.
Article in Archives of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mahvash disease is a rare autosomal recessive condition caused by biallelic inactivating variants in the GCGR gene, impairing glucagon signaling and leading to alpha-cell hyperplasia and pancreatic neuroendocrine tumors (PNETs). Fewer than 20 cases have been reported, and the clinical impact of heterozygous variants remains unclear. Case Presentation: We report a family with a novel GCGR splice-site variant (c.1176+1_1176+7delGTGCCCG). The index case, a 61-year-old woman, presented with extensive pancreatic cystic disease and was found to be homozygous for the variant. She developed well-differentiated PNETs and underwent total pancreatectomy. Her sister, also homozygous, had similar clinical features and surgical history. In contrast, the heterozygous brother and two sons showed mild biochemical changes, such as elevated glucagon levels and small pancreatic cysts, without overt disease. The two homozygous sisters required pancreatic surgery followed by insulin and enzyme replacement therapy, whereas heterozygous carriers are currently being managed with biochemical and imaging surveillance. This family's phenotype suggests a broader spectrum of GCGR-related disease. While homozygous individuals displayed classic Mahvash disease, heterozygotes exhibited subtle biochemical and structural pancreatic changes, indicating possible semidominant expression. These findings are consistent with emerging evidence that monoallelic receptor pathway mutations may produce mild or subclinical phenotypes. This case challenges the classical recessive model of Mahvash disease and highlights the potential for disease expression in heterozygous carriers. These findings suggest that heterozygosity is not entirely silent and underline the need to reconsider surveillance recommendations for GCGR heterozygotes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.